Contrast-enhanced ultrasound imaging: State of the art

Journal of Medical Ultrasound

Volumn 13, Issue 3, 2005, Pages 109-126

  Liu, Ji Bin ^a   Wansaicheong, Gervais ^a   Merton, Daniel A ^a   Forsberg, Flemming ^a   Goldberg, Barry B ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Harmonic imaging; Microbubble; Tumor diagnosis; Ultrasound contrast agents; Ultrasound imaging technology

Indexed keywords

AI 700; BISPHERE; BR 14; BUTANE; BY 963; CONTRAST MEDIUM; ECHO CONTRAST MEDIUM; FLUOROCARBON; FS 069; MRX 408; NC 100100; PERFLEXANE; PERFLUTREN; QFX; QUANTISON; SHU 508; SONOVUE; UNCLASSIFIED DRUG;

ARTIFACT; BILIARY TRACT DISEASE; CEREBROVASCULAR DISEASE; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DOG; DOPPLER ECHOGRAPHY; DRUG DELIVERY SYSTEM; ECHOCARDIOGRAPHY; ECHOGRAPHY; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; GENE THERAPY; HEART DISEASE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE QUALITY; IMAGING SYSTEM; INJURY; KIDNEY DISEASE; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM DISEASE; MALIGNANT NEOPLASTIC DISEASE; MICROBUBBLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID DISEASE; PROSTATE CANCER; PROSTATE DISEASE; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; THYROID DISEASE; VASCULAR DISEASE;

EID: 33845871214     PISSN: 09296441     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6441(09)60100-4     Document Type: Review

References (97)

1. Harvey CJ, Pilcher JM, Eckersley RJ, et al. Advances in ultrasound. Clin Radiol 2002;57:157-77.
2. Hohmann J, Albrecht T, Oldenburg A, et al. Liver metastases in cancer: detection with contrast-enhanced ultrasonography. Abdom Imaging 2004;29:669-81.
3. Barr R. Seeking consensus: contrast ultrasound in radiology. Eur J Radiol 2002;41:207-16.
4. Forsberg F, Shi WT. Physics of contrast microbubbles. In: Goldberg BB, Raichen JS, Forsberg F, eds. Ultrasound Contrast Agents, 2nd edition. London: Martin Dunitz, 2001.
5. Lencioni R, Cioni C, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. Eur Radiol 2002;12:151-65.
6. Simpson DH, Chin CT, Burns PN. Pulse Inversion Doppler: a new method for detecting nonlinear echoes from microbubble contrast agents. IEEE Trans Ultrason Ferroelec Freq Contr 1999;46:372-82.
7. Forsberg F, Liu JB, Chiou HJ, et al. Comparison of fundamental and wideband harmonic contrast imaging of liver tumors. Ultrasonics 2000;38:110-3.
8. Wilson SR, Burns PN, Muradali D, et al. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 2000;215:153-61.
9. Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med 2004;25:249-56.
10. Porter TR, Xie F. Transient myocardial contrast after initial exposure to diagnostic ultrasound pressures with minute doses of intravenously injected microbubbles. Circulation 1995;92:2391-5.
11. Colon PJ, Richards DR, Moreno CA, et al. Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacification with FS069 during fundamental and second harmonic imaging. J Am Soc Echocardiogr 1997;10:602-7.
12. Broillet A, Puginier J, Ventrone R, et al. Assessment of myocardial perfusion by intermittent harmonic power Doppler using SonoVue, a new ultrasound contrast agent. Invest Radiol 1998;33:209-15.
13. Porter TR, Kricsfeld D, Cheatham S, et al. The effect of ultrasound frame rate on perfluorocarbon-exposed sonicated dextrose albumin microbubble size and concentration when insonifying at different flow rates, transducer frequencies and acoustic outputs. J Am Soc Echocardiogr 1997;10:593-601.
14. Kamiyama N, Moriyasu F, Mine Y, et al. Analysis of flash echo from contrast agent for designing optimal ultrasound diagnostic systems. Ultrasound Med Biol 1999;25:411-20.
15. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-83.
16. Bouakaz A, Krenning BJ, Vletter WB, et al. Contrast superharmonic imaging: a feasibility study. Ultrasound Med Biol 2003;29:547-53.
17. Kim JH, Eun HW, Lee HK, et al. Renal perfusion abnormality. Coded harmonic angio US with contrast agent. Acta Radiol 2003;44:166-71.
18. Murthy TH, Locricchio E, Kuersten B, et al. Power Doppler myocardial contrast echocardiography using an improved multiple frame triggered harmonic angio technique. Echocardiography 2001;18:191-6.
19. Kaul S. Instrumentation for contrast echocardiography: technology and techniques. Am J Cardiol 2002; 90(Suppl):8J-14J.
20. Simpson DH, Chin CT, Burns PN. Pulse inversion Doppler: a new method for detecting nonlinear echoes from microbubble contrast agents. IEEE Trans Ultrason Ferroelec Freq Contr 1999;46:372-82.
21. Van Camp G, Ay T, Pasquet A, et al. Quantification of myocardial blood flow and assessment of its transmural distribution with real-time power modulation myocardial contrast echocardiography. J Am Soc Echocardiogr 2003;16:263-70.
22. Shankar PM, Dala Krishna P, Newhouse VL. Advantages of subharmonic over second harmonic backscatter for contrast-to-tissue echo enhancement. Ultrasound Med Biol 1998;24:395-9.
23. Shi WT, Forsberg F, Hall AL, et al. Subharmonic imaging with microbubble contrast agents: initial results. Ultrason Imaging 1999;21:79-94.
24. Bartolotta TV, Midiri M, Quaia E, et al. Benign focal liver lesions: spectrum of findings on SonoVue-enhanced pulse-inversion ultrasonography. Eur Radiol 2005;15:1643-9.
25. Passamonti M, Vercelli A, Azzaretti A, et al. Characterization of focal liver lesions with a new ultrasound contrast agent using continuous low acoustic power imaging: comparison with contrast enhanced spiral CT. Radiol Med (Torino) 2005;109:358-69.
26. Ricci P, Laghi A, Cantisani V, et al. Contrast-enhanced sonography with SonoVue: enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2005;184:821-7.
27. Luo BM, Wen YL, Yang HY, et al. Differentiation between malignant and benign nodules in the liver: use of contrast C3-MODE technology. World J Gastroenterol 2005;11:2402-7.
28. Ignee A, Weiper D, Schuessler G, et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z Gastroenterol 2005;43:289-94.
29. Giorgio A, Ferraioli G, Tarantino L, et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 2004;183:1319-26.
30. Kim SH, Lee JM, Lee JY, et al. Value of contrast-enhanced sonography for the characterization of focal hepatic lesions in patients with diffuse liver disease: receiver operating characteristic analysis. AJR Am J Roentgenol 2005;184:1077-84.
31. Ding H, Wang WP, Huang BJ, et al. Imaging of focal liver lesions: low-mechanical-index real-time ultrasonography with SonoVue. J Ultrasound Med 2005;24: 285-97.
32. Zhou X, Strobel D, Haensler J, et al. Hepatic transit time: indicator of the therapeutic response to radiofrequency ablation of liver tumours. Br J Radiol 2005;78: 433-6.
33. Niizawa G, Ikegami T, Matsuzaki Y, et al. Monitoring of hepatocellular carcinoma, following proton radiotherapy, with contrast-enhanced color Doppler ultrasonography. J Gastroenterol 2005;40:283-90.
34. Hirota M, Kaneko T, Sugimoto H, et al. Intrahepatic circulatory time analysis of an ultrasound contrast agent in liver cirrhosis. Liver Int 2005;25:337-42.
35. Hotta N, Tagaya T, Maeno T, et al. Advanced dynamic flow imaging with contrast-enhanced ultrasonography for the evaluation of tumor vascularity in liver tumors. Clin Imaging 2005;29:34-41.
36. Solbiati L, Ierace T, Tonolini M, et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004; 51(Suppl):S19-23.
37. Vallone P, Gallipoli A, Izzo F, et al. Local ablation procedures in primary livertumors: Levovist US versus spiral CT to evaluate therapeutic results. Anticancer Res 2003;23:5075-9.
38. Ding H, Kudo M, Onda H, et al. Evaluation of post-treatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 2001;221: 721-30.
39. Meloni MF, Goldberg SN, Livraghi T, et al. Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol 2001;177:375-80.
40. Minami Y, Kudo M, Kawasaki T, et al. Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol 2004;183:153-6.
41. Johnson DB, Duchene DA, Taylor GD, et al. Contrast-enhanced ultrasound evaluation of radiofrequency ablation of the kidney: reliable imaging of the thermolesion. J Endourol 2005;19:248-52.
42. Torzilli G, Olivari N, Moroni E, et al. Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis. Liver Transpl 2004;10(2 Suppl 1):S34-8.
43. Liu JB, Merton DA, Forsberg F, et al. Contrast-enhanced US for Monitoning Radiofrequency Ablation of Canine Prostate: Initial Results. The 90th Scientific Assembly and Annual Meeting Program of the Radiological Society of North America, November 28-December 3, 2004, Chicago, IL, p386.
44. Miller AP, Nanda NC. Contrast echocardiography: new agents. Ultrasound Med Biol 2004;30:425-34.
45. Stewart MJ. Contrast echocardiography. Heart 2003; 89:342-8.
46. Cheng SC, Dy TC, Feinstein SB. Contrast echocardiography: review and future directions. Am J Cardiol 1998;81(12A):41G-8G.
47. Cwaig J, Xie F, O'Leary E, et al. Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material. Am Heart J 2000;139:675-83.
48. Della Martina A, Meyer-Wiethe K, Allemann E, et al. Ultrasound contrast agents for brain perfusion imaging and ischemic stroke therapy. J Neuroimaging 2005;15: 217-32.
49. Droste DW, Metz RJ. Clinical utility of echocontrast agents in neurosonology. Neurol Res 2004;26:754-9.
50. Argalia G, De Bernardis S, Mariani D, et al. Ultrasonographic contrast agent: evaluation of time-intensity curves in the characterisation of solitary thyroid nodules. Radiol Med (Torino) 2002;103:407-13.
51. Spiezia S, Farina R, Cerbone G, et al. Analysis of color Doppler signal intensity variation after Levovist injection: a new approach to the diagnosis of thyroid nodules. J Ultrasound Med 2001;20:223-31,quiz 233.
52. Mazzeo S, Caramella D, Marcocci C, et al. Contrast-enhanced color Doppler ultrasonography in suspected parathyroid lesions. Acta Radiol 2000;41:412-6.
53. Tamano M, Yoneda M, Kojima K, et al. Evaluation of esophageal varices using contrast-enhanced coded harmonic ultrasonography. J Gastroenterol Hepatol 2004;19:572-5.
54. Sato T, Yamazaki K, Toyota J, et al. Perforating veins in recurrent esophageal varices evaluated by endoscopic color Doppler ultrasonography with a galactose-based contrast agent. J Gastroenterol 2004;39:422-8.
55. Hata J, Kamada T, Haruma K, et al. Evaluation of bowel ischemia with contrast-enhanced US: initial experience. Radiology 2005;236:712-5.
56. Fukuta N, Kitano M, Maekawa K, et al. Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J Gastroenterol 2005;40: 247-55.
57. Robotti D, Cammarota T, Debani P, et al. Activity of Crohn's disease: value of color power Doppler and contrast-enhanced ultrasonography. Abdom Imaging 2004;29:648-52.
58. Rapaccini GL, Pompili M, Orefice R, et al. Contrast-enhanced power Doppler of the intestinal wall in the evaluation of patients with Crohn's disease. Scand J Gastroenterol 2004;39:188-94.
59. Incesu L, Yazicioglu AK, Selcuk MB, et al. Contrast-enhanced power Doppler US in the diagnosis of acute appendicitis. Eur J Radiol 2004;50:201-9.
60. Parente F, Greco S, Molteni M, et al. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn's disease. A prospective comparison with conventional ultrasound, X-ray studies, and ileocolonoscopy. Gut 2004;53:1652-7.
61. Khalili K, Metser U, Wilson SR. Hilar biliary obstruction: preliminary results with Levovist-enhanced sonography. AJR Am J Roentgenol 2003;180:687-93.
62. Hirooka Y, Naitoh Y, Goto H, et al. Contrast-enhanced endoscopic ultrasonography in gallbladder diseases. Gastrointest Endosc 1998;8:406-10.
63. Kim KA, Park CM, Park SW, et al. Contrast-enhanced power Doppler US: is it useful in the differentiation of gallbladder disease? Clin Imaging 2002;26:319-24.
64. Fischer T, Muhler M, Kroncke TJ, et al. Early postoperative ultrasound of kidney transplants: evaluation of contrast medium dynamics using time-intensity curves. Rofo 2004;176:472-7.
65. Siracusano S, Quaia E, Bertolotto M, et al. The application of ultrasound contrast agents in the characterization of renal tumors. World J Urol 2004;22:316-22.
66. Ascenti G, Gaeta M, Magno C, et al. Contrast-enhanced second-harmonic sonography in the detection of pseudocapsule in renal cell carcinoma. AJR Am J Roentgenol 2004;182:1525-30.
67. Darge K, Moeller RT, Trusen A, et al. Diagnosis of vesicoureteric reflux with low-dose contrast-enhanced harmonic ultrasound imaging. Pediatr Radiol 2005;35: 73-8.
68. Fregene TA, Khanuja PS, Noto AC, et al. Tumor-associated angiogenesis in prostate cancer. Anticancer Res 1993;13:2377-81.
69. Brawer MK. Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer 1996;78:345-9.
70. Rifkin MD, Tublin ME, Cheruvu SK, et al. Ultrasound contrast enhanced color Doppler: initial results in the evaluation of the prostate. Radiology 1997;205:280.
71. Eckersley RJ, Butler-Barnes JA, Blomley MJ, et al. Quantitative microbubble enhanced transrectal ultrasound (TRUS) as a tool for monitoring anti-androgen therapy in prostate carcinoma: work in progress. Radiology 1998;209:280.
72. Bogers HA, Sedelaar JPM, Beerlage HP, et al. Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Urology 1999;54:97-104.
73. Frauscher F, Klauser A, Halpern EJ, et al. Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 2001;357:1849-50.
74. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced US for detection. Radiology 2001;219:219-25.
75. Halpern EJ, McCue PA, Aksnes AK, et al. Contrast enhanced sonography of the prostate with Sonazoid: comparison with whole mount prostatectomy specimens in twelve patients. Radiology 2002;222:361-6.
76. Frauscher F, Klauser A, Volgger H, et al. Comparison of contrast-enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on prostate cancer detection. J Urol 2002;167:1648-52.
77. Halpern EJ, Frauscher F, Rosenberg M, et al. Directed biopsy during contrast enhanced sonography of the prostate. AJR Am J Roentgenol 2002;178:915-9.
78. Kitano M, Kudo M, Maekawa K, et al. Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004; 53:854-9.
79. Rickes S, Unkrodt K, Neye H, et al. Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echo-enhanced power Doppler sonography. Scand J Gastroenterol 2002;37:1313-20.
80. Hohl C, Schmidt T, Haage P, et al. Phase-inversion tissue harmonic imaging compared with conventional B-mode ultrasound in the evaluation of pancreatic lesions. Eur Radiol 2004;14:1109-17.
81. Itoh T, Hirooka Y, Itoh A, et al. Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 2005;100:144-52.
82. Melany ML, Grant EG, Duerinckx AJ, et al. Ability of a phase shift contrast agent to improve imaging of the main renal arteries. Radiology 1997;205:147-52.
83. Missouris CG, Allen CM, Balen FG, et al. Non-invasive screening for renal artery stenosis with ultrasound contrast enhancement. J Hypertens 1996;14:519-24.
84. Claudon M, Rohban T. Levovist in the diagnosis of renal artery stenosis: results of a controlled multicenter study. Radiology 1997;205:242.
85. Drelich-Zbroja A, Jargiello T, Drelich G, et al. Renal artery stenosis: value of contrast-enhanced ultrasonography. Abdom Imaging 2004;29:518-24.
86. Liu JB, Merton DA, Goldberg BB, et al. Contrast-enhanced 2D and 3D sonography for evaluation of intra-abdominal hemorrhage. J Ultrasound Med 2002; 21:161-9.
87. Catalano O, Lobianco R, Sandomenico F, et al. Real-time, contrast-enhanced sonographic imaging in emergency radiology. Radiol Med (Torino) 2004;108: 454-69.
88. Miele V, Buffa V, Stasolla A, et al. Contrast-enhanced ultrasound with second generation contrast agent in traumatic liver lesions. Radiol Med (Torino) 2004;108: 82-91.
89. Goldberg BB, Merton DA, Liu JB, et al. Sentinel lymph nodes in a swine model with melanoma: contrast-enhanced lymphatic US. Radiology 2004;230: 727-34.
90. Goldberg BB, Merton DA, Liu JB, et al. Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes. J Ultrasound Med 2005;24: 953-65.
91. Price RJ, Kaul S. Contrast ultrasound targeted drug and gene delivery: an update on a new therapeutic modality. J Cardiovasc Pharmacol Ther 2002;7:171-80.
92. Bekeredjian R, Chen S, Frenkel PA, et al. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation 2003;108:1022-6.
93. Shohet RV, Chen S, Zhou YT, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000;101: 2554-6.
94. Lindner JR, Dayton PA, Coggins MP, et al. Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation 2000;102: 531-8.
95. Crowder KC, Hughes MS, Marsh JN, et al. Augmented and selective delivery of liquid perfluorocarbon nanoparticles to melanoma cells with noncavitational ultrasound. Ultrasonics 2003;1:532-5.
96. Unger EC, Hersh E, Vannan M, et al. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 2001;44:45-54.
97. Huang SL, McPherson DD, MacDonald RC. Ultrasound in conjunction with an ultrasonic reflective transfection agent enhances gene delivery to cells. J Am Coll Cardiol 2002;39(5 Suppl):228A.